Aktienanalyse zu Sanofi SA (SNY)SNYSanofi SA

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sanofi SA is currently a hold. The stock is trading at $40.07, which is significantly below the analyst price target of EUR 80, indicating potential upside. However, the RSI is at 37.151, suggesting it is in a bearish trend, and the forward P/E ratio of 8.5911 indicates it is undervalued compared to its earnings potential. The main risk is the negative sentiment surrounding Dupixent's patent cliff, which could impact future revenues.

3 analysts cover SNY: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 79.36.